Celltrion acquires approval of world’s first anticancer antibody biosimilar ‘Truxima’
Celltrion announced on the 22nd that Truxima(generic name: rituximab), an antibody biosimilar for the treatment of hematologic malignancy and autoimmune disease, has acquired sales approval from the European Medicines Agency(EMA). The EMA has approved the treatment for all indications of referenc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
